RPS6KB1 and breast cancer: Here, we have shown that BC-LI-0186 specifically inhibits the LRS-RagD pathway by directly binding to LRS, but not Sestrin2 (Fig. 1e and Supplementary Fig. 1g), and specifically inhibits leucine-induced S6K phosphorylation (Supplementary Fig. 1a).